Nuvo Pharmaceuticals™ Announces Director Election Results of its Annual General Meeting
May 11 2017 - 5:02PM
PR Newswire (US)
MISSISSAUGA, ON, May 11, 2017 /PRNewswire/ - Nuvo Pharmaceuticals
Inc. (Nuvo or the Company) (TSX:NRI) a commercial healthcare
company with a portfolio of commercial products and pharmaceutical
manufacturing capabilities, today announced that at its 2017 Annual
and Special Meeting of Shareholders held in Toronto, all nominees listed in the management
proxy circular dated April 5, 2017
were elected as directors of the Company.
The detailed results of the votes by proxy are as follows:
Director
Nominees
|
NUMBER OF
SHARES
|
PERCENTAGE OF
VOTES CAST
|
FOR
|
WITHHELD
|
FOR
|
WITHHELD
|
Daniel
Chicoine
|
2,997,859
|
82,678
|
97.32
|
2.68
|
David A.
Copeland
|
2,999,892
|
80,645
|
97.38
|
2.62
|
Anthony E.
Dobranowski
|
3,002,978
|
77,559
|
97.48
|
2.52
|
Robert
Harris
|
3,011,591
|
68,946
|
97.76
|
2.24
|
John C.
London
|
2,999,920
|
80,617
|
97.38
|
2.62
|
Dr. Jacques
Messier
|
2,999,298
|
81,239
|
97.36
|
2.64
|
About Nuvo Pharmaceuticals
Inc.
Nuvo (TSX:NRI) is a commercial healthcare company with
a portfolio of commercial products and pharmaceutical manufacturing
capabilities. Nuvo has three commercial products that are
available in a number of countries; Pennsaid 2%, Pennsaid and the
heated lidocaine/tetracaine patch. Pennsaid 2% is sold
in the U.S. by Horizon Pharma plc (NASDAQ:HZNP) and is available
for partnering in certain other territories around the
world. Nuvo manufactures Pennsaid for the global market and
Pennsaid 2% for the U.S. market at its FDA, Health Canada and E.U.
approved manufacturing facility in Varennes, Québec. For additional
information, please visit www.nuvopharmaceuticals.com.
SOURCE Nuvo Pharmaceuticals Inc.
Copyright 2017 PR Newswire